



DIONYSSIOS KATSAROS

Italy

Personal statement

I had the privilege and honor to start my career as a young fellow doing research in Gynaecologic Oncology some 35 years ago at the National Cancer Institute, Bethesda, Md, USA. I also had the privilege, after all these years, to recently receive from ESGO a Certificate of Professional Recognition.

Working in an Academic Center gave me the opportunity to work on both surgical and medical aspects of patients obtaining a holistic approach of the management of gynaecologic malignancies, from diagnosis to terminal stage patients. I firmly believe that the best cancer treatments are not good enough, and I'm committed to advancing the mission of ESGO through education, investigation and training.

I know that working together we can accomplish a great deal and advance gynaecologic care for women. Compassion, commitment, and flexibility are the three qualities with which I identify best. I am comfortable taking the lead on projects, but equally happy to join an effort as ancillary support. Given the variety of personalities and backgrounds represented in collaborative groups, differences of opinion are to be expected; I often find myself attempting to bridge these gaps to come to a common solution by listening to all parties and considering each point of view.

Whichever role I may be taking on in a leadership group, I remain focused on the goals of the team and lend support wherever I can, whether it be with part of the work load or by simply listening to a colleague. My general personality is upbeat and I try to inject humour whenever possible when I can sense tension in a group.

I believe I will be able to constructively contribute to the ESGO mission in advancing the care for women with gynaecologic malignancies and to assist in development of academic and clinical offerings which benefit clinicians across the Europe and Worldwide.

Thank you for your consideration.

NIH type BIOGRAPHICAL SKETCH (CV)

NAME	POSITION TITLE
Dionyssios Katsaros Date of Birth: May 3, 1958 Nationality: Italian/Greek Married, 3 children Work Address: Dept Surgical Sciences, Gynecologic Oncology, University of Turin, Corso Spezia, 60, 10126, Turin, ITALY Tel: +390113131996 Fax: +390113134859 d.katsaros@libero.it	Full Professor of Obstetrics and Gynecology, University of Turin, ITALY. Director Clinical Research in Gynecologic Oncology, University of Torino, ITALY. Chief Officer Tumor Board in Gynecologic Oncology and Breast Cancer Unit ESGO (European Society of Gynaecological Oncology) Professional Recognition (2023)
COMMON USER NAME DKatsaros	

EDUCATION/TRAINING

INSTITUTION AND LOCATION	DEGREE (if applicable)	MM/YYYY	FIELD OF STUDY
University of Turin, Italy, School of Medicine	MD degree	11/1988	Medicine
University of Turin, Italy, School of Medicine, Residency in Obstetrics and Gynecology	Specialist in Obstetrics and Gynecology	11/1992	Obstetrics- Gynecology
University of Rome, "La Sapienza", Rome, Italy	PhD degree	6/1997	Gynecologic Oncology
National Cancer Institute, Bethesda, Md, USA	Research Associate Fellowship, Tumor Immunology and Biology	1985-1988	Oncology
European Institute of Oncology, Milan Italy	Pelvic Surgery Fellowship	12/2011	Gynecologic Oncology

A. Personal Statement

As a physician-scientist, Prof. Katsaro's career has focused for over 35 years on Surgical and Medical management of patients as well as clinical and translational research regarding gynecologic malignancies mostly ovarian, endometrial, cervical and breast cancer.

He is now Director of Clinical and Translational studies of the S Anna Hospital at the University of Turin, Italy conducting at national and international level phase II-III clinical as well as translational studies in collaboration with known Institutions and Universities worldwide and through ENGOT and IGCS network.

As a teacher and student mentor he is a permanent member of Faculty staff at the University of Turin (medical students, residents and fellows) for Gynecology and Gynecologic Oncology.

He fluently speaks Greek, Italian, English; Romanian, good level of basic German language.

B. Positions and Honors

Positions and Employment

1997-1998 Assistant Gynecologist, San Luigi Hospital, University of Turin, Italy

1998-2002 Associate Gynecologist, S. Anna Hospital, University of Turin, Italy

2002-2008 Chief Officer, Oncological Day Hospital, S. Anna Hospital, University of Turin, Italy

2008-present Director of Research, S. Anna Hospital, University of Turin, Italy

2014-present Professor of Obstetrics and Gynecology, University of Turin, Italy

Other Experience and Professional Memberships

1999-present EORTC (European Organization for Research and Treatment of Cancer, Gynecologic Oncology Group), Vice Chairman (2007-2011), Chairman of Translational Research (2005-2007), Chairman of Ovarian Tumor Site Committee (2007-2011), Member of Protocol Committee (2005-present).

1985-1988 Research Associate Fellowship, Tumor Immunology and Biology, National Cancer Institute, Bethesda, Md, USA

1991-1992 Visiting Scientist (Clinical Fellow), Gynecologic Oncology, MD Anderson Cancer Center, Houston, TX, USA

1994 Visiting Scientist, Gynecologic Oncology, Royal Infirmary of Edinburgh, Edinburgh, Scotland.

2003-2006- **PATENT Recipient** in collaboration with Dr. EP Diamandis, Mount Sinai Hospital, University
2007 of Toronto ,Canada for: “Novel Kallikrein gene (KLK 15)” , “Diagnostic methods for ovarian carcinoma”, “CEAL1/gene, complete dcs alternatively spliced”

Awards and Other Professional Activities

Italian Society of Gynecologic Oncology Award (1989-1990-1995);

European School of Oncology (1998) award;

AACR Pezcoller Foundation Award 2000;

Membership of EORTC-ENGOT (European Cancer Societies of Studies)-SIOG (Italian Gynecologic Oncology)-IGCS. (International Gynecologic Cancer Society), ESGO (European Gynecologic Cancer Society) MaNGO (Founder, Mario Negri Gynecologic Oncology National Group)

Reviewer/Editorial board member of Scientific papers for numerous journals (Cancers, Gynecol Oncol, Int J Cancer, Clin Cancer Res, Am J Ob-Gyn , Anticancer Res, Int J Oncology).

C. Peer-reviewed Publications

Principal author and co-author of 228 (pubmed indexed) papers;

Author and co-author of more than 450 abstracts and non pubmed papers (101) presented in National and mostly International meetings since 1986 (available on request)

D. Research Support

Numerous grant support received in the past 20 years from University, Local Cancer Organizations, Cooperative Research groups and Industry.

AIRC (Italian Association for Cancer Research), National Institute of Health (USA), Ontario Institute Of Cancer Research (Canada), Department of Surgical Sciences, University of Turin (Italy) to mention a few

- 1) Post, C. C., de Boer, S. M., Powell, M. E., Mileschkin, L., **Katsaros, D.**, Bessette, P., ... & Creutzberg, C. L. (2025). Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial. *The Lancet Oncology*, 26(10), 1370-1381.
- 2) Wang, J., **Katsaros, D.**, Wang, Z., Ma, L., Casetta, E., Fei, P., ... & Yu, H. (2025). Mitochondrial tRNA fragment, mt-tRF-Tyr-GTA-001 (tRF-21-X3OJI8EWB), in breast cancer and its potential clinical implications. *Breast Cancer Research and Treatment*, 211(3), 675-685.
- 3) Volinsky-Fremont, S., Horeweg, N., Andani, S., Barkey Wolf, J., Lafarge, M. W., de Kroon, C. D. **Katsaros, D.**, ... & Bosse, T. (2024). Prediction of recurrence risk in endometrial cancer with multimodal deep learning. *Nature medicine*, 30(7), 1962-1973.
- 4) Wakkerman, F. C., Wu, J., Putter, H., Jürgenliemk-Schulz, I. M., Jobsen, J. J., Lutgens, L. C., **Katsaros, D.**; ... & Horeweg, N. (2024). Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials. *The lancet oncology*, 25(6), 779-789.
- 5) Oaknin, Ana, et al. "Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial." *The Lancet* 403.10421 (2024): 31-43.
- 6) Wang, Z., **Katsaros, D.**, Wang, J., Biglio, N., Hernandez, B. Y., Fei, P., ... & Yu, H. (2023). Machine learning-based cluster analysis of immune cell subtypes and breast cancer survival. *Scientific Reports*, 13(1), 18962.
- 7) Kenter, G. G., Greggi, S., Vergote, I., Katsaros, D., Kobierski, J., van Doorn, H., **Katsaros, D.**; ... & EORTC-55994 Study Group. (2023). Randomized phase III study comparing neoadjuvant chemotherapy followed by surgery versus chemoradiation in stage IB2-IIB cervical cancer: EORTC-55994. *Journal of Clinical Oncology*, 41(32), 5035-5043.
- 8) Borella, F., Fucina, S., Mangherini, L., Cosma, S., Carosso, A. R., Cusato, J., Cassoni, P., Bertero, L., **Katsaros, D.**, Benedetto, C. "Hormone Receptors and Epithelial Ovarian Cancer: Recent Advances in Biology and Treatment Options. *Biomedicines*. 2023; 11 (8): 2157."
- 9) Velle A., Pesenti C., Grassi T., Beltrame L., Martini P., Jaconi M., Agostinis F., Calura E., **Katsaros D.**, Borella F., Fruscio R., D'Incalci M., Marchini S., Romualdi C., "A comprehensive investigation of histotype-specific microRNA and their variants in Stage I epithelial ovarian cancers", 2023, "International Journal of Cancer", "152", "9"1989", "2001
- 10) Vergote I., Gonzalez-Martin A., Lorusso D., Gourley C., Mirza M.R., Kurtz J.-E., Okamoto A., Moore K., Kridelka F., McNeish I., Reuss A., Votan B., du Bois A., Mahner S., Ray-Coquard I., Kohn E.C., Berek J.S., Tan D.S.P., Colombo N., Zang R., Concin N., O'Donnell D., Rauh-Hain A., Herrington C.S., Marth C., Poveda A., Fujiwara K., Stuart G.C.E., Oza A.M., Bookman M.A., Grimm C., Berger R., Chang T.-C., Ochiai K., Gebiski V., Davis A., Beale P., Denys H., Vandecaveye V., Cancido dos Reis F.J., Del Pilar Estevez Diz M., Stuart G., MacKay H., Carey M., Cibula D., Dunder (path) P., Dorigo O., Berek J., Saadeh A., Boere I., Lok C., Coronado P., Ottevanger N., Tan D.S., Ng J., Gonzalez Martin A., Oaknin A., Perez Fidalgo A., Lu K., López-Zavala C., Gómez-García E.M., Paoletti X., Joly F., Bookman M., Arend R., Fujiwara H., Hasegawa K., Bruchim I., Tsoref D., Oda K., Enomoto T., Michel D., Kim H.-S., Lee J.-Y., Mukhopadhyay A., **Katsaros D.**, Pignata S., Scambia G., Kohn E., Lee J.-M., Nicum S., Farrelly L., Sehouli J., Keller M., Braicu E., Bjørge L., Auranen A., Welch S., Heinzelmann

V., Roxburgh P., Glasspool R., Zhu J., participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research,"Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup",2022,"**The Lancet Oncology**", "23", "8", "e374", "e384"

- 11) Pesenti C., Beltrame L., Velle A., Fruscio R., Jaconi M., Borella F., Cribiù F.M., Calura E., Venturini L.V., Lenoci D., Agostinis F., **Katsaros D.**, Panini N., Bianchi T., Landoni F., Miozzo M., D'Incalci M., Brenton J.D., Romualdi C., Marchini S., "Copy number alterations in stage I epithelial ovarian cancer highlight three genomic patterns associated with prognosis",2022,"**European Journal of Cancer**", "171", "85", "95"
- 12) Wang J., **Katsaros D.**, Biglia N., Fu Y., Benedetto C., Loo L., Wang Z., Yu H., "LncRNA ZNF582-AS1 Expression and Methylation in Breast Cancer and Its Biological and Clinical Implications",2022,"**Cancers**", "14", "11", "2788", "", ""
- 13) Wortman B.G., Post C.C.B., Powell M.E., Khaw P., Fyles A., D'Amico R., Haie-Meder C., Jürgenliemk-Schulz I.M., McCormack M., Do V., **Katsaros D.**, Bessette P., Baron M.H., Nout R.A., Whitmarsh K., Mileschkin L., Lutgens L.C.H.W., Kitchener H.C., Brooks S., Nijman H.W., Astreinidou E., Putter H., Creutzberg C.L., de Boer S.M., "Radiation Therapy Techniques and Treatment-Related Toxicity in the PORTEC-3 Trial: Comparison of 3-Dimensional Conformal Radiation Therapy Versus Intensity-Modulated Radiation Therapy",2022,"**International Journal of Radiation Oncology Biology Physics**", "112", "2", "390", "399"
- 14) Fu Y., **Katsaros D.**, Biglia N., Wang Z., Pagano I., Tius M., Tiirikainen M., Rosser C., Yang H., Yu H., "Vitamin D receptor upregulates lncRNA TOPORS-AS1 which inhibits the Wnt/ β -catenin pathway and associates with favorable prognosis of ovarian cancer",2021,"**Scientific Reports**", "11", "1", "7484", "", ""
- 15) Di Liello R., Arenare L., Raspagliesi F., Scambia G., Pisano C., Colombo N., Frezzini S., Tognon G., Artioli G., Gadducci A., Lauria R., Ferrero A., Cinieri S., De Censi A., Breda E., Scollo P., De Giorgi U., Lissoni A.A., **Katsaros D.**, Lorusso D., Salutati V., Cecere S.C., Lapresa M., Nardin M., Bogani G., Distefano M., Greggi S., Gargiulo P., Schettino C., Gallo C., Daniele G., Califano D., Perrone F., Pignata S., Piccirillo M.C., "Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial",2021,"**International journal of gynecological cancer : official journal of the International Gynecological Cancer Society**", "31", "10", "1348", "1355"
- 16) Giannone G., Scotto G., **Katsaros D.**, De Giorgi U., Farolfi A., Borella F., Cosma S., Ferrero A., Mangiacotti S., Villa M., Tuninetti V., Ghisoni E., Turinetti M., Mittica G., Gemmiti S., Zavallone L., Aglietta M., Pasini B., Di Maio M., Valabrega G., "Hypersensitivity to platinum salts according to BRCA status in ovarian cancer: A retrospective analysis of clinical outcomes and systematic review of literature",2021,"**Gynecologic Oncology**", "162", "1", "80", "87"
- 17) Daniele G., Raspagliesi F., Scambia G., Pisano C., Colombo N., Frezzini S., Tognon G., Artioli G., Gadducci A., Lauria R., Ferrero A., Cinieri S., De Censi A., Breda E., Scollo P., De Giorgi U., Lissoni A.A., **Katsaros D.**, Lorusso D., Salutati V., Cecere S.C., Zaccarelli E., Nardin M., Bogani G., Distefano M., Greggi S., Piccirillo M.C., Fossati R., Giannone G., Arenare L., Gallo C., Perrone F., Pignata S., "Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: The phase IV MITO-16A/MaNGO-OV2A study",2021,"**International Journal of Gynecological Cancer**", "31", "6", "875", "882"
- 18) Post C.C.B., de Boer S.M., Powell M.E., Mileschkin L., **Katsaros D.**, Bessette P., Haie-Meder C., Ottevanger N.P.B., Ledermann J.A., Khaw P., D'Amico R., Fyles A., Baron M.H., Kitchener H.C., Nijman H.W., Lutgens L.C.H.W., Brooks S., Jürgenliemk-Schulz I.M., Feeney A., Goss G., Fossati R., Ghatage P., Leary A., Do V., Lissoni A.A., McCormack M., Nout R.A., Verhoeven-Adema K.W., Smit V.T.H.B.M., Putter H., Creutzberg C.L., "Long-Term Toxicity and Health-Related Quality of Life After Adjuvant Chemoradiation Therapy or Radiation Therapy Alone for High-Risk Endometrial Cancer in

the Randomized PORTEC-3 Trial",2021,"**International Journal of Radiation Oncology Biology Physics**", "109", "4", "975", "986"

- 19) Cosma S., Borella F., Carosso A., Sciarrone A., Cusato J., Corcione S., Mengozzi G., Preti M., **Katsaros D.**, Di Perri G., Benedetto C., "The "scar" of a pandemic: Cumulative incidence of COVID-19 during the first trimester of pregnancy",2021,"**Journal of Medical Virology**", "93", "1", "537", "540"
- 20) Kalachand R.D., Stordal B., Madden S., Chandler B., Cunningham J., Goode E.L., Ruscito I., Braicu E.I., Sehoul J., Ignatov A., Yu H., **Katsaros D.**, Mills G.B., Lu K.H., Carey M.S., Timms K.M., Kupryjanczyk J., Rzepecka I.K., Podgorska A., McAlpine J.N., Swisher E.M., Bernards S.S., O'Riain C., O'Toole S., O'Leary J.J., Bowtell D.D., Thomas D.M., Prieske K., Joosse S.A., Woelber L., Chaudhry P., Häfner N., Runnebaum I.B., Hennessy B.T., "BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis",2020,"**Journal of the National Cancer Institute**", "112", "12", "1190", "1203"
- 21) Borella F., Bertero L., Morrone A., Gambella A., Bovetti M., Cosma S., Carosso A., **Katsaros D.**, Gemmiti S., Preti M., Valabrega G., Scotto G., Cassoni P., Benedetto C., "Brain metastases from ovarian cancer: Current evidence in diagnosis, treatment, and prognosis",2020,"**Cancers**", "12", "8", "2156", "1", "22"
- 22) Mittica G., Goia M., Gambino A., Scotto G., Fonte M., Senetta R., Aglietta M., Borella F., Sapino A., **Katsaros D.**, Maggiorotto F., Ghisoni E., Giannone G., Tuninetti V., Genta S., Eusebi C., Momi M., Cassoni P., Valabrega G., "Validation of Androgen Receptor loss as a risk factor for the development of brain metastases from ovarian cancers",2020,"**Journal of Ovarian Research**", "13", "1", "53", "", ""
- 23) D'Ambrosio C., Erriquez J., Arigoni M., Capellero S., Mittica G., Ghisoni E., Borella F., **Katsaros D.**, Privitera S., Ribotta M., Maldì E., Di Nardo G., Berrino E., Venesio T., Ponzzone R., Vaira M., Hall D., Jimenez-Linan M., Paterson A.L., Calogero R.A., Brenton J.D., Valabrega G., Di Renzo M.F., Olivero M., "PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma",2020,"**Cells**", "9", "2", "", "", ""
- 24) Borella F., Ghisoni E., Giannone G., Cosma S., Benedetto C., Valabrega G., **Katsaros D.**, "Immune checkpoint inhibitors in epithelial ovarian cancer: An overview on efficacy and future perspectives",2020,"**Diagnostics**", "10", "3", "146", "", ""
- 25) Calura E., Ciciani M., Sambugaro A., Paracchini L., Benvenuto G., Milite S., Martini P., Beltrame L., Zane F., Fruscio R., Marchette M.D., Borella F., Tognon G., Ravaggi A., **Katsaros D.**, Bignotti E., Odicino F., D'Incalci M., Marchini S., Romualdi C., "Transcriptional characterization of stage I epithelial ovarian cancer: A multicentric study",2019,"**Cells**", "8", "12", "1554", "", ""
- 26) Borella F., Lucchino F., Bertero L., Ribotta M., Castellano I., Carosso A., Cosma S., **Katsaros D.**, Benedetto C., "Clinico-pathological features of gynecological myopericytoma: a challenging diagnosis in an exceptional location",2019,"**Virchows Archiv**", "475", "6", "763", "770"
- 27) Tassi R.A., Gambino A., Ardighieri L., Bignotti E., Todeschini P., Romani C., Zanotti L., Bugatti M., Borella F., **Katsaros D.**, Tognon G., Sartori E., Odicino F., Romualdi C., Ravaggi A., "FXD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients",2019,"**British Journal of Cancer**", "121", "7", "584", "592"
- 28) de Boer S.M., Powell M.E., Mileskin L., **Katsaros D.**, Bessette P., Haie-Meder C., Ottevanger P.B., Ledermann J.A., Khaw P., D'Amico R., Fyles A., Baron M.-H., Jürgenliemk-Schulz I.M., Kitchener H.C., Nijman H.W., Wilson G., Brooks S., Gribaudo S., Provencher D., Hanzen C., Kruitwagen R.F., Smit V.T.H.B.M., Singh N., Do V., Lissoni A., Nout R.A., Feeney A., Verhoeven-Adema K.W., Putter H., Creutzberg C.L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P.J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Lutgens L.C.H.W., Hollema H., Pras E.,

Snyers A., Westerveld G.H., Jobsen J.J., Slot A., Mens J.M., Stam T.C., Van Triest B., Van der Steen-Banasik E.M., De Winter K.A.J., Quinn M.A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Colombo A., Carinelli S., Ferrero A., Artioli G., Davidson C., McLachlin C.M., Ghatage P., Rittenberg P.V.C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N., PORTEC Study Group, "Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial", 2019, **The Lancet Oncology**, "20", "9", "1273", "1285"

- 29) Wang Z., **Katsaros D.**, Biglia N., Shen Y., Fu Y., Tiirikainen M., Yu H., "Low expression of WWC1, a tumor suppressor gene, is associated with aggressive breast cancer and poor survival outcome", 2019, **FEBS Open Bio**, "9", "7", "1270", "1280"
- 30) Wang Z., **Katsaros D.**, Biglia N., Shen Y., Loo L., Yu X., Lin H., Fu Y., Chu W.-M., Fei P., Ni Y., Jia W., Deng X., Qian B., Yu H., "ER α upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF- κ B in breast cancer", 2019, **Breast Cancer Research and Treatment**, "175", "2", "353", "368"
- 31) Ghisoni E., Maggiorotto F., Borella F., Mittica G., Genta S., Giannone G., **Katsaros D.**, Sciarillo A., Ferrero A., Sarotto I., Erriquez J., Di Renzo M.F., Aglietta M., Valabrega G., "TOP2A as marker of response to pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancers", 2019, **Journal of Ovarian Research**, "12", "1", "17", "", ""
- 32) Arisio R., Borella F., Porpiglia M., Durando A., Bellino R., Bau M.G., De Sanctis C., Danese S., Benedetto C., **Katsaros D.**, "Axillary dissection vs. No axillary dissection in breast cancer patients with positive sentinel lymph node: A single institution experience", 2019, **In Vivo**, "33", "6", "1941", "1947"
- 33) Vergote I., Coens C., Nankivell M., Kristensen G.B., Parmar M.K.B., Ehlen T., Jayson G.C., Johnson N., Swart A.M., Verheijen R., McCluggage W.G., Perren T., Panici P.B., Kenter G., Casado A., Mendiola C., Stuart G., Reed N.S., Kehoe S., Tropé G. C., Dobbs S., Essapen S., Hoskins P., Green J., Gilby E., Van Baal M., Twigg J., Van Der Burg M.E.L., Godfrey K., Lacave A.J., Angioli R., Nath R., Chin K., Redman C., Lotocki R., Olaitan A., Mosgaard B., Rustin G., Ind T., Persic M., Hogg M., Van Der Velden J., Ledermann J., Peter Sykes P.S., Madhavan K., Kannisto P., Hird V., Evans A., Sandvei R. R., Gauthier P., Cruickshank D.J., Ottevanger P.B., Pearson S., Kitchener H., Hall M., Bessette P., Pecorelli S., Gerdin E., Lopes T., Fish A., Barlow C., Van Eygen K., Floquet A., Tholander B., Gul N., Gornall R., Luesley D., Kirwan P., Symonds P., Henry R., Poole D., McNeish I., Hocking M., Sammaria A., Speiser P., Leblanc E., Green J.A., De Oliveira C.F., Grimshaw R., Zola P., Parkin D., Lamb M., Hong A., Gillespie A., Hamid A., Ahmed A., Plante M., De Valk B., Nordin A., Clamp A., Perez D., Graham Dark G.D., Ferguson M., MacGregor C., Skailes G., Jones R., Cawdell G., Leeson S., Elit L., Dittrich C., Gotlieb W., Cullimore J., Crosse B., Ridley P., Head A., Nieto J., Awwad S., Brinkmann D., Eustace D., Hindley A., **Katsaros D.**, Popadiuk C., Kristeller T., Redman C., Chan S., Marth C., Yiannakis D., Lankaster K., Beynon G., Suhail A., Indrajit F., Quigley M., Adeyemi O., Lofts F., McNally O., Tristram A., Lee M., Counsell R., Gleeson N., Papadopoulos A., Maggino T., Honkoop A., Ghatage P., Vermorken J.B., De Greve J., Boman K., Petru E., EORTC, MRC CHORUS study investigators, "Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials", 2018, **The Lancet Oncology**, "19", "12", "1680", "1687"
- 34) Wang Z., **Katsaros D.**, Biglia N., Shen Y., Fu Y., Loo L.W.M., Jia W., Obata Y., Yu H., "High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival", 2018, **Breast Cancer Research and Treatment**, "171", "2", "261", "271"
- 35) Ghisoni E., **Katsaros D.**, Maggiorotto F., Aglietta M., Vaira M., De Simone M., Mittica G., Giannone G., Robella M., Genta S., Lucchino F., Marocco F., Borella F., Valabrega G., Ponzzone R., "A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: A two-centers experience", 2018, **Journal of Ovarian Research**, "11", "1", "42", "", ""

- 36) de Boer S.M., Powell M.E., Mileschkin L., **Katsaros D.**, Bessette P., Haie-Meder C., Ottevanger P.B., Ledermann J.A., Khaw P., Colombo A., Fyles A., Baron M.-H., Jürgenliemk-Schulz I.M., Kitchener H.C., Nijman H.W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L.C.H.W., Smit V.T.H.B.M., Singh N., Do V., D'Amico R., Nout R.A., Feeney A., Verhoeven-Adema K.W., Putter H., Creutzberg C.L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P.J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R.F.P.M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J.J., Slot A., Mens J.-W.M., Stam T.C., Van Triest B., Van der Steen - Banasik E.M., De Winter K.A.J., Quinn M.A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A.A., Ferrero A., Artioli G., Davidson C., McLachlin C.M., Ghatage P., Rittenberg P.V.C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N., PORTEC study group, "Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial", 2018, "**The Lancet Oncology**", "19", "3", "295", "309"
- 37) de Boer S.M., Wortman B.G., Bosse T., Powell M.E., Singh N., Hollema H., Wilson G., Chowdhury M.N., Mileschkin L., Pyman J., **Katsaros D.**, Carinelli S., Fyles A., McLachlin C.M., Haie-Meder C., Duvillard P., Nout R.A., Verhoeven-Adema K.W., Putter H., Creutzberg C.L., Smit V.T.H.B.M., for PORTEC Study Group, "Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer", 2018, "**Annals of Oncology**", "29", "2", "424", "430"
- 38) Martini P., Paracchini L., Caratti G., Mello-Grand M., Fruscio R., Beltrame L., Calura E., Sales G., Ravaggi A., Bignotti E., Odicino F.E., Sartori E., Perego P., **Katsaros D.**, Craparotta I., Chiorino G., Cagnin S., Mannarino L., Ceppi L., Mangioni C., Ghimenti C., D'Incalci M., Marchini S., Romualdi C., "LncRNAs as novel indicators of patients' prognosis in stage I epithelial ovarian cancer: A retrospective and multicentric study", 2017, "**Clinical Cancer Research**", "23", "9", "2356", "2366"
- 39) D'Hondt V., Lacroix-Triki M., Jarlier M., Boissiere-Michot F., Puech C., Coopman P., **Katsaros D.**, Freiss G., "High PTPN13 expression in high grade serous ovarian carcinoma is associated with a better patient outcome", 2017, "**Oncotarget**", "8", "56", "95662", "95673"
- 40) de Boer S.M., Powell M.E., Mileschkin L., **Katsaros D.**, Bessette P., Haie-Meder C., Ottevanger P.B., Ledermann J.A., Khaw P., Colombo A., Fyles A., Baron M.-H., Kitchener H.C., Nijman H.W., Kruitwagen R.F., Nout R.A., Verhoeven-Adema K.W., Smit V.T., Putter H., Creutzberg C.L., for the, PORTEC study group, "Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial", 2016, "**The Lancet Oncology**", "17", "8", "1114", "1126"
- 41) Calura E., Paracchini L., Fruscio R., DiFeo A., Ravaggi A., Peronne J., Martini P., Sales G., Beltrame L., Bignotti E., Tognon G., Milani R., Clivio L., Dell'Anna T., Cattoretti G., **Katsaros D.**, Sartori E., Mangioni C., Ardighieri L., D'Incalci M., Marchini S., Romualdi C., "A prognostic regulatory pathway in stage I epithelial ovarian cancer: New hints for the poor prognosis assessment", 2016, "**Annals of Oncology**", "27", "8", "1511", "1519"
- 42) Despierre E., Vergote I., Anderson R., Coens C., **Katsaros D.**, Hirsch F.R., Boeckx B., Varella-Garcia M., Ferrero A., Ray-Coquard I., Green J.A., Steer C., Berns E.M.J.J., Casado A., Lambrechts D., Jimeno A., "Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy (Targ Oncol, 10, 2015 (583-596), 10.1007/s11523-015-0369-6)", 2016, "**Targeted Oncology**", "11", "3", "429", ""
- 43) Erriquez J., Olivero M., Mittica G., Scalzo M.S., Vaira M., De Simone M., Ponzzone R., **Katsaros D.**, Aglietta M., Calogero R., Di Renzo N.F., Valabrega G., "Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer", 2016, "**Oncotarget**", "7", "18", "26181", "26191"

- 44) Lu L., **Katsaros D.**, Risch H.A., Canuto E.M., Biglia N., Yu H., "MicroRNA let-7a modifies the effect of self-renewal gene HIWI on patient survival of epithelial ovarian cancer", 2016, "**Molecular Carcinogenesis**", "55", "4", "357", "365"
- 45) Lu L., **Katsaros D.**, Canuto E.M., Biglia N., Risch H.A., Yu H., "LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis", 2016, "**Gynecologic Oncology**", "141", "1", "121", "127"
- 46) Fu Y., Biglia N., Wang Z., Shen Y., Risch H.A., Lu L., Canuto E.M., Jia W., **Katsaros D.**, Yu H., "Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer", 2016, "**Gynecologic Oncology**", "143", "3", "642", "649"
- 47) Jean S., Li J., **Katsaros D.**, Wubbenhorst B., Maxwell K.N., Fishbein L., McLane M.W., Benedetto C., Canuto E.M., Mitra N., Zhang L., Nathanson K.L., Tanyi J.L., "Paclitaxel is necessary for improved survival in epithelial ovarian cancers with homologous recombination gene mutations", 2016, "**Oncotarget**", "7", "30", "48577", "48585"
- 48) Colombo N., Creutzberg C., Amant F., Bosse T., González-Martón A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., Sessa C., Abal M., Altundag O., Banerjee S., Casado A., De Agustín L.C., Cibula D., Del Campo J.-M., Emons G., Goffin F., González-Martín A., Greggi S., Haie-Meder C., **Katsaros D.**, Kesic V., Kurzeder C., Lax S., Lécuru F., Levy T., Lorusso D., Mäenpää J., Matias-Guiu X., Morice P., Nijman H.W., Powell M., Reed N., Rodolakis A., Salvesen H., Sehouli J., Taylor A., Westermann A., Zeimet A.G., The ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group, "ESMO-ESGO-ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up", 2016, "**Annals of Oncology**", "27", "1", "16", "41"
- 49) Despierre E., Vergote I., Anderson R., Coens C., **Katsaros D.**, Hirsch F.R., Boeckx B., Varella-Garcia M., Ferrero A., Ray-Coquard I., Berns E.M.J.J., Casado A., Lambrechts D., Jimeno A., "Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy", 2015, "**Targeted Oncology**", "10", "4", "583", "596"
- 50) Shen Y., Wang Z., Loo L.W.M., Ni Y., Jia W., Fei P., Risch H.A., **Katsaros D.**, Yu H., "LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer", 2015, "**Breast Cancer Research and Treatment**", "154", "3", "473", "482"
- 51) Yan X., Hu Z., Feng Y., Hu X., Yuan J., Zhao S.D., Zhang Y., Yang L., Shan W., He Q., Fan L., Kandalafi L.E., Tanyi J.L., Li C., Yuan C.-X., Zhang D., Yuan H., Hua K., Lu Y., **Katsaros D.**, Huang Q., Montone K., Fan Y., Coukos G., Boyd J., Sood A.K., Rebbeck T., Mills G.B., Dang C.V., Zhang L., "Comprehensive Genomic Characterization of Long Non-coding RNAs across Human Cancers", 2015, "**Cancer Cell**", "28", "4", "2143", "529", "540"
- 52) Wang Z., **Katsaros D.**, Shen Y., Fu Y., Canuto E.M., Benedetto C., Lu L., Chu W.-M., Risch H.A., Yu H., "Biological and clinical significance of MAD2L1 and BUB1, genes frequently appearing in expression signatures for breast cancer prognosis", 2015, "**PLoS ONE**", "10", "8", "0136246", "", ""
- 53) Shen Y., **Katsaros D.**, Loo L.W.M., Hernandez B.Y., Chong C., Canuto E.M., Biglia N., Lu L., Risch H., Chu W.-M., Yu H., "Prognostic and predictive values of long non-coding RNA LINC00472 in breast cancer", 2015, "**Oncotarget**", "6", "11", "8579", "8592"
- 54) Su D., **Katsaros D.**, Xu S., Xu H., Gao Y., Biglia N., Feng J., Ying L., Zhang P., Benedetto C., Yu H., "ADP-ribosylation factor-like 4C (ARL4C), a novel ovarian cancer metastasis suppressor, identified by integrated genomics", 2015, "**American Journal of Translational Research**", "7", "2", "242", "256"

- 55) Vergote I.B., Jimeno A., Joly F., **Katsaros D.**, Coens C., Despierre E., Marth C., Hall M., Steer C.B., Colombo N., Lesoin A., Casado A., Reinthaller A., Green J., Buck M., Ray-Coquard I., Ferrero A., Favier L., Reed N.S., Curé H., Pujade-Lauraine E., "Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study", 2014, "**Journal of Clinical Oncology**", "32", "4", "320", "326"
- 56) Valente G., Morani F., Nicotra G., Fusco N., Peracchio C., Titone R., Alabiso O., Arisio R., **Katsaros D.**, Benedetto C., Isidoro C., "Expression and clinical significance of the autophagy proteins BECLIN 1 and LC3 in ovarian cancer", 2014, "**BioMed Research International**", "2014", "462658", "", ""
- 57) Hu X., Feng Y., Zhang D., Zhao S.D., Hu Z., Greshock J., Zhang Y., Yang L., Zhong X., Wang L.-P., Jean S., Li C., Huang Q., **Katsaros D.**, Montone K.T., Tanyi J.L., Lu Y., Boyd J., Nathanson K.L., Li H., Mills G.B., Zhang L., "A Functional Genomic Approach Identifies FAL1 as an Oncogenic Long Noncoding RNA that Associates with BMI1 and Represses p21 Expression in Cancer", 2014, "**Cancer Cell**", "26", "3", "344", "357"
- 58) Esposito F., Cecere S.C., Magazzino F., **Katsaros D.**, Ottaiano A., Gadducci A., Pisano C., Scalone S., Rabaiotti E., Salutati V., Cormio G., Canuto E.M., Greggi S., Savarese A., Marinaccio M., Scollo P., Santeufemia D.A., Sacco C., Facchini G., Pignata S., "Second-line chemotherapy in recurrent clear cell ovarian cancer: Results from the Multicenter Italian Trials in Ovarian cancer (MITO-9)", 2014, "**Oncology (Switzerland)**", "86", "5-6", "351", "358"
- 59) Pignata S., Scambia G., **Katsaros D.**, Gallo C., Pujade-Lauraine E., De Placido S., Bologna A., Weber B., Raspagliesi F., Panici P.B., Cormio G., Sorio R., Cavazzini M.G., Ferrandina G., Breda E., Murgia V., Sacco C., Cinieri S., Salutati V., Ricci C., Pisano C., Greggi S., Lauria R., Lorusso D., Marchetti C., Selvaggi L., Signoriello S., Piccirillo M.C., Di Maio M., Perrone F., "Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial", 2014, "**The Lancet Oncology**", "15", "4", "396", "405"
- 60) Benedetti Panici P., Basile S., Salerno M.G., Di Donato V., Marchetti C., Perniola G., Palagiano A., Perutelli A., Maneschi F., Lissoni A.A., Signorelli M., Scambia G., Tateo S., Mangili G., **Katsaros D.**, Campagnutta E., Donadello N., Greggi S., Melpignano M., Raspagliesi F., Cormio G., Grassi R., Franchi M., Giannarelli D., Fossati R., Torri V., Crocè C., Mangioni C., "Secondary analyses from a randomized clinical trial: Age as the key prognostic factor in endometrial carcinoma", 2014, "**American Journal of Obstetrics and Gynecology**", "210", "4", "363.e1", "363.e10"
- 61) Lu L., Risch E., Deng Q., Biglia N., Picardo E., **Katsaros D.**, Yu H., "An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival", 2013, "**Carcinogenesis**", "34", "9", "2024", "2030"
- 62) Calura E., Fruscio R., Paracchini L., Bignotti E., Ravaggi A., Martini P., Sales G., Beltrame L., Clivio L., Ceppi L., Di Marino M., Nerini I.F., Zanotti L., Cavalieri D., Cattoretti G., Perego P., Milani R., **Katsaros D.**, Tognon G., Sartori E., Pecorelli S., Mangioni C., D'Incalci M., Romualdi C., Marchini S., "MiRNA landscape in stage I epithelial ovarian cancer defines the histotype specificities", 2013, "**Clinical Cancer Research**", "19", "15", "4114", "4123"
- 63) Ying L., Su D., Zhu J., Ma S., **Katsaros D.**, Yu H., "Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer", 2013, "**Oncology Letters**", "5", "4", "1315", "1320"
- 64) Hu X., Guo J., Zheng L., Li C., Zheng T.M., Tanyi J.L., Liang S., Benedetto C., Mitidieri M., **Katsaros D.**, Zhao X., Zhang Y., Huang Q., Zhang L., "The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer", 2013, "**Molecular Cancer Research**", "11", "3", "240", "250"

- 65) Lu L., Zhu G., Zhang C., Deng Q., **Katsaros D.**, Mayne S.T., Risch H.A., Mu L., Canuto E.M., Gregori G., Benedetto C., Yu H., "Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer", 2012, "**Breast Cancer Research and Treatment**", "136", "3", "875", "883"
- 66) Lu L., **Katsaros D.**, Mayne S.T., Risch H.A., Benedetto C., Canuto E.M., Yu H., "Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer", 2012, "**Carcinogenesis**", "33", "11", "2119", "2125"
- 67) Ratner E.S., Keane F.K., Lindner R., Tassi R.A., Paranjape T., Glasgow M., Nallur S., Deng Y., Lu L., Steele L., Sand S., Muller R.-U., Bignotti E., Bellone S., Boeke M., Yao X., Pecorelli S., Ravaggi A., **Katsaros D.**, Zelterman D., Cristea M.C., Yu H., Rutherford T.J., Weitzel J.N., Neuhausen S.L., Schwartz P.E., Slack F.J., Santin A.D., Weidhaas J.B., "A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer", 2012, "**Oncogene**", "31", "42", "4559", "4566"
- 68) Marchini S., Poynor E., Barakat R.R., Clivio L., Cinquini M., Fruscio R., Porcu L., Bussani C., D'Incalci M., Erba E., Romano M., Cattoretto G., **Katsaros D.**, Koff A., Luzzatto L., "The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer", 2012, "**Clinical Cancer Research**", "18", "16", "4313", "4324"
- 69) Parma G., Mancari R., Del Conte G., Scambia G., Gadducci A., Hess D., **Katsaros D.**, Sessa C., Rinaldi A., Bertoni F., Vitali A., Catapano C.V., Marsoni S., Van De Velde H., Colombo N., "An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens", 2012, "**International Journal of Gynecological Cancer**", "22", "5", "792", "800"
- 70) Li N., Zhong X., Lin X., Guo J., Zou L., Tanyi J.L., Shao Z., Liang S., Wang L.-P., Hwang W.-T., **Katsaros D.**, Montone K., Zhao X., Zhang L., "Lin-28 homologue A (LIN28A) promotes cell cycle progression via regulation of cyclin-dependent kinase 2 (CDK2), cyclin D1 (CCND1), and cell division cycle 25 homolog A (CDC25A) expression in cancer", 2012, "**Journal of Biological Chemistry**", "287", "21", "17386", "17397"
- 71) Mu L., Tuck D., **Katsaros D.**, Lu L., Schulz V., Perincheri S., Menato G., Scarampi L., Harris L., Yu H., "Favorable outcome associated with an IGF-1 ligand signature in breast cancer", 2012, "**Breast Cancer Research and Treatment**", "133", "1", "321", "331"
- 72) Zeng H., Irwin M.L., Lu L., Risch H., Mayne S., Mu L., Deng Q., Scarampi L., Mitidieri M., **Katsaros D.**, Yu H., "Physical activity and breast cancer survival: An epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1", 2012, "**Breast Cancer Research and Treatment**", "133", "1", "127", "135"
- 73) Casado A., Penninckx B., Reed N., van der Burg M.E.L., Berns E.M.J.J., **Katsaros D.**, Ferrero A., Mota F., Jimeno A., Vermorken J., Pecorelli S., Coens C., Vergote I., "EORTC Gynecological Cancer Group on the frontline of practice-changing clinical trials", 2012, "**European Journal of Cancer, Supplement**", "10", "1", "66", "75"
- 74) Su D., Xu H., Feng J., Gao Y., Gu L., Ying L., **Katsaros D.**, Yu H., Xu S., Qi M., "PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer", 2012, "**Journal of Translational Medicine**", "10", "1", "31", "", ""
- 75) Li N., Kaur S., Greshock J., Lassus H., Zhong X., Wang Y., Leminen A., Shao Z., Hu X., Liang S., **Katsaros D.**, Huang Q., Bützow R., Weber B.L., Coukos G., Zhang L., "A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer", 2012, "**Cancer Research**", "72", "1", "154", "164"

- 76) Magazzino F., **Katsaros D.**, Ottaiano A., Gadducci A., Pisano C., Sorio R., Rabaiotti E., Scambia G., Cormio G., Scarampi L., Greggi S., Savarese A., Marinaccio M., Scillo P., Pignata S., "Surgical and medical treatment of clear cell ovarian cancer, results from the multicenter italian trials in ovarian cancer (MITO) 9 retrospective study", 2011, "**International Journal of Gynecological Cancer**", "21", "6", "1063", "1070"
- 77) Sasaroli D., Gimotty P.A., Pathak H.B., Hammond R., Kougoumtzidou E., **Katsaros D.**, Buckanovich R., Devarajan K., Sandaltzopoulos R., Godwin A.K., Scholler N., Coukos G., "Novel surface targets and serum biomarkers from the ovarian cancer vasculature", 2011, "**Cancer Biology and Therapy**", "12", "3", "169", "180"
- 78) Lu L., Schwartz P., Scarampi L., Rutherford T., Canuto E.M., Yu H., **Katsaros D.**, "MicroRNA let-7a: A potential marker for selection of paclitaxel in ovarian cancer management", 2011, "**Gynecologic Oncology**", "122", "2", "366", "371"
- 79) Huang J., Zhang L., Greshock J., Colligon T.A., Wang Y., Ward R., **Katsaros D.**, Lassus H., Butzow R., Godwin A.K., Testa J.R., Nathanson K.L., Gimotty P.A., Coukos G., Weber B.L., Degenhardt Y., "Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome", 2011, "**Genes Chromosomes and Cancer**", "50", "8", "606", "618"
- 80) Lu L., Zhang C., Zhu G., Irwin M., Risch H., Menato G., Mitidieri M., **Katsaros D.**, Yu H., "Telomerase expression and telomere length in breast cancer and their associations with adjuvant treatment and disease outcome", 2011, "**Breast Cancer Research**", "13", "3", "R56", "", ""
- 81) Friedlander M., Trimble E., Tinker A., Alberts D., Avall-Lundqvist E., Brady M., Harter P., Pignata S., Pujade-Lauraine E., Sehouli J., Vergote I., Beale P., Bekkers R., Calvert P., Copeland L., Glasspool R., Gonzalez-Martin A., **Katsaros D.**, Kim J.W., Miller B., Provencher D., Rubinstein L., Atri M., Zeimet A., Bacon M., Kitchener H., Stuart G.C.E., "Clinical trials in recurrent ovarian cancer", 2011, "**International Journal of Gynecological Cancer**", "21", "4", "771", "775"
- 82) **Katsaros D.**, Gribaudo S., "The proper use of multimodality treatment in locally advanced cervical cancer", 2011, "**Gynecologic Oncology**", "121", "2", "422", "423"
- 83) Lu L., **Katsaros D.**, Zhu Y., Hoffman A., Luca S., Marion C.E., Mu L., Risch H., Yu H., "Let-7a regulation of insulin-like growth factors in breast cancer", 2011, "**Breast Cancer Research and Treatment**", "126", "3", "687", "694"
- 84) Marchini S., Cavalieri D., Fruscio R., Calura E., Garavaglia D., Nerini I.F., Mangioni C., Cattoretti G., Clivio L., Beltrame L., **Katsaros D.**, Scarampi L., Menato G., Perego P., Chiorino G., Buda A., Romualdi C., D'Incalci M., "Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: A retrospective study of two independent tumour tissue collections", 2011, "**The Lancet Oncology**", "12", "3", "273", "285"
- 85) Fuso L., Evangelista A., Pagano E., Piovano E., Perotto S., Mazzola S., Bertoldo E., La Porta M.R., Rosmino C., Furbatto G., Abate S., Di Costanzo G., Trossarelli G., Baù M.G., Carnino F., Gambaro G., Piantanida P., Alabiso O., Galletto L., Zavallone L., Rossi A., Barbero M., Tessa M., **Katsaros D.**, Danese S., Brignolo P., Gorzegno G., Grillo R., Apolone G., Ciccone G., Zola P., "Variation in gynecological oncology follow-up practice: Attributable to cancer centers or to patient characteristics? A Piedmont Regional Oncology Network Study", 2011, "**Tumori**", "97", "5", "551", "558"
- 86) Papanastasiou A.D., Pampalakis G., **Katsaros D.**, Sotiropoulou G., "Netrin-1 overexpression is predictive of ovarian malignancies", 2011, "**Oncotarget**", "2", "5", "363", "367"

- 87) Bayani J., Marrano P., Graham C., Zheng Y., Li L., **Katsaros D.**, Lassus H., Butzow R., Squire J.A., Diamandis E.P., "Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas", 2011, "**Molecular Oncology**", "5", "1", "48", "60"
- 88) Qian B., **Katsaros D.**, Lu L., Canuto E.M., Benedetto C., Beeghly-Fadiel A., Yu H., "IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics", 2011, "**Oncology Reports**", "25", "1", "203", "213"
- 89) Yang X., Lin X., Zhong X., Kaur S., Li N., Liang S., Lassus H., Wang L., **Katsaros D.**, Montone K., Zhao X., Zhang Y., Bützow R., Coukos G., Zhang L., "Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells", 2010, "**Cancer Research**", "70", "22", "9463", "9472"
- 90) Hoskins P., Vergote I., Cervantes A., Tu D., Stuart G., Zola P., Poveda A., Provencher D., **Katsaros D.**, Ojeda B., Ghatage P., Grimshaw R., Casado A., Elit L., Mendiola C., Sugimoto A., D'Hondt V., Oza A., Germa J.R., Roy M., Brotto L., Chen D., Eisenhauer E.A., "Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel", 2010, "**Journal of the National Cancer Institute**", "102", "20", "1547", "1556"
- 91) Ortolan E., Arisio R., Morone S., Bovino P., Lo-Buono N., Nacci G., Parrotta R., **Katsaros D.**, Rapa I., Migliaretti G., Ferrero E., Volante M., Funaro A., "Functional role and prognostic significance of CD157 in ovarian carcinoma", 2010, "**Journal of the National Cancer Institute**", "102", "15", "1160", "1177"
- 92) Pampalakis G., Diamandis E.P., **Katsaros D.**, Sotiropoulou G., "Down-regulation of dicer expression in ovarian cancer tissues", 2010, "**Clinical Biochemistry**", "43", "3", "324", "327"
- 93) Signorelli M., Lissoni A.A., Cormio G., **Katsaros D.**, Pellegrino A., Selvaggi L., Ghezzi F., Scambia G., Zola P., Grassi R., Milani R., Giannice R., Caspani G., Mangioni C., Floriani I., Rulli E., Fossati R., "Modified radical hysterectomy versus extrafascial hysterectomy in the treatment of stage I endometrial cancer: Results from the ILIAD randomized study", 2009, "**Annals of Surgical Oncology**", "16", "12", "3431", "3441"
- 94) Pecorelli S., Ray-Coquard I., Tredan O., Colombo N., Parma G., Tisi G., Katsaròs D., Lhommé C., Lissoni A.A., Vermorken J.B., du Bois A., Poveda A., Frigerio L., Barbieri P., Carminati P., Brienza S., Guastalla J.P., "Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes", 2009, "**Annals of Oncology**", "21", "4", "759", "765"
- 95) Collino F., Revelli A., Massobrio M., **Katsaros D.**, Schmitt-Ney M., Camussi G., Bussolati B., "Epithelial-mesenchymal transition of ovarian tumor cells induces an angiogenic monocyte cell population", 2009, "**Experimental Cell Research**", "315", "17", "2982", "2994"
- 96) Gumireddy K., Li A., Gimotty P.A., Klein-Szanto A.J., Showe L.C., **Katsaros D.**, Coukos G., Zhang L., Huang Q., "KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer", 2009, "**Nature Cell Biology**", "11", "11", "1297", "1304"
- 97) Pecorelli S., Favalli G., Gadducci A., **Katsaros D.**, Panici P.B., Carpi A., Scambia G., Ballardini M., Nanni O., Conte P., "Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: Final results of the after-6 protocol 1", 2009, "**Journal of Clinical Oncology**", "27", "28", "4642", "4648"
- 98) Qian B., **Katsaros D.**, Lu L., Preti M., Durando A., Arisio R., Mu L., Yu H., "High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF- β 1", 2009, "**Breast Cancer Research and Treatment**", "117", "1", "131", "140"

- 99) Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Cormio G., **Katsaros D.**, Frigerio L., Mereu L., Ghezzi F., Manzione L., Lauria R., Breda E., Alletti D.G., Ballardini M., Vernaglia A., Sorio R., Tumolo S., Musso P., Magni G., Pisano C., Morabito A., "Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study", 2009, "**Critical Reviews in Oncology/Hematology**", "71", "3", "233", "241"
- 100) Lu L., **Katsaros D.**, Shaverdashvili K., Qian B., Wu Y., de la Longrais I.A.R., Preti M., Menato G., Yu H., "Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II", 2009, "**European Journal of Cancer**", "45", "12", "2212", "2218"
- 101) Su D., Smith S.M., Preti M., Schwartz P., Rutherford T.J., Menato G., Danese S., Ma S., Yu H., **Katsaros D.**, "Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel", 2009, "**Cancer**", "115", "11", "2453", "2463"
- 102) Gadducci A., **Katsaros D.**, Zola P., Scambia G., Ballardini M., Pasquini E., Fertonani C., Maggi L., Pecorelli S., Conte P.F., "Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: Results of an open noncomparative phase 2 multicenter italian study (after-6 protocol 2)", 2009, "**International Journal of Gynecological Cancer**", "19", "4", "615", "619"
- 103) Mu L., **Katsaros D.**, Wiley A., Lu L., De La Longrais I.A.R., Smith S., Khubchandani S., Sochirca O., Arisio R., Yu H., "Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics", 2009, "**Breast Cancer Research and Treatment**", "115", "1", "151", "162"
- 104) Liang S., Yang N., Pan Y., Deng S., Lin X., Yang X., **Katsaros D.**, Roby K.F., Hamilton T.C., Connolly D.C., Coukos G., Zhang L., "Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation", 2009, "**PLoS ONE**", "4", "1", "e4295", "", ""
- 105) Lissoni A.A., Colombo N., Pellegrino A., Parma G., Zola P., **Katsaros D.**, Chiari S., Buda A., Landoni F., Peiretti M., Dell'Anna T., Fruscio R., Signorelli M., Grassi R., Floriani I., Fossati R., Torri V., Rulli E., "A phase II, randomized trial of neo-adjuvant chemotherapy comparing a three-drug combination of paclitaxel, ifosfamide, and cisplatin (TIP) versus paclitaxel and cisplatin (TP) followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The Snap-02 Italian Collaborative Study", 2009, "**Annals of Oncology**", "20", "4", "660", "665"
- 106) Yang N., Kaur S., Volinia S., Greshock J., Lassus H., Hasegawa K., Liang S., Leminen A., Deng S., Smith L., Johnstone C.N., Chen X.-M., Liu C.-G., Huang Q., **Katsaros D.**, Calin G.A., Weber B.L., Bützow R., Croce C.M., Coukos G., Zhang L., "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer", 2008, "**Cancer Research**", "68", "24", "10307", "10314"
- 107) Panici P.B., Basile S., Maneschi F., Lissoni A.A., Signorelli M., Scambia G., Angioli R., Tateo S., Mangili G., **Katsaros D.**, Garozzo G., Campagnutta E., Donadello N., Greggi S., Melpignano M., Raspagliesi F., Ragni N., Cormio G., Grassi R., Franchi M., Giannarelli D., Fossati R., Torri V., Amoroso M., Crocè C., Mangioni C., "Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: Randomized clinical trial", 2008, "**Journal of the National Cancer Institute**", "100", "23", "1707", "1716"
- 108) Mu L., **Katsaros D.**, Lu L., Preti M., Durando A., Arisio R., Yu H., "TGF- β 1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival", 2008, "**British Journal of Cancer**", "99", "8", "1357", "1363"

- 109) Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Cormio G., **Katsaros D.**, Villa A., Mereu L., Ghezzi F., Manzione L., Lauria R., Breda E., Alletti D.G., Ballardini M., Lombardi A.V., Sorio R., Mangili G., Priolo D., Magni G., Morabito A., "Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: Results from the SOCRATES retrospective study", 2008, "**BMC Cancer**", "8", "252", "", ""
- 110) Zhang L., Volinia S., Bonome T., Calin G.A., Greshock J., Yang N., Liu C.-G., Giannakakis A., Alexiou P., Hasegawa K., Johnstone C.N., Megraw M.S., Adams S., Lassus H., Huang J., Kaur S., Liang S., Sethupathy P., Leminen A., Simossis V.A., Sandaltzopoulos R., Naomoto Y., **Katsaros D.**, Gimotty P.A., DeMichele A., Huang Q., Bützow R., Rustgi A.K., Weber B.L., Birrer M.J., Hatzigeorgiou A.G., Croce C.M., Coukos G., "Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer", 2008, "**Proceedings of the National Academy of Sciences of the United States of America**", "105", "19", "7004", "7009"
- 111) Chanrion M., Negre V., Fontaine H., Salvetat N., Bibeau F., Mac Grogan G., Mauriac L., **Katsaros D.**, Molina F., Theillet C., Darbon J.-M., "A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer", 2008, "**Clinical Cancer Research**", "14", "6", "1744", "1752"
- 112) Yang N., Huang J., Greshock J., Liang S., Barchetti A., Hasegawa K., Kim S., Giannakakis A., Li C., O'Brien-Jenkins A., **Katsaros D.**, Bützow R., Coukos G., Zhang L., "Transcriptional regulation of PIK3CA oncogene by NF- κ B in ovarian cancer microenvironment", 2008, "**PLoS ONE**", "3", "3", "e1758", "", ""
- 113) Ferrandina G., Ludovisi M., Lorusso D., Pignata S., Breda E., Savarese A., Del Medico P., Scaltriti L., **Katsaros D.**, Priolo D., Scambia G., "Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer", 2008, "**Journal of Clinical Oncology**", "26", "6", "890", "896"
- 114) Lu L., **Katsaros D.**, Wiley A., De La Longrais I.A.R., Puopolo M., Yu H., "Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression", 2008, "**Cancer Investigation**", "26", "2", "185", "192"
- 115) Huang Q., Gumireddy K., Schrier M., le Sage C., Nagel R., Nair S., Egan D.A., Li A., Huang G., Klein-Szanto A.J., Gimotty P.A., **Katsaros D.**, Coukos G., Zhang L., Puré E., Agami R., "The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis", 2008, "**Nature Cell Biology**", "10", "2", "202", "210"
- 116) Giannakakis A., Sandaltzopoulos R., Greshock J., Liang S., Huang J., Hasegawa K., Li C., O'Brien-Jenkins A., **Katsaros D.**, Weber B.L., Simon C., Coukos G., Zhang L., "miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer", 2008, "**Cancer Biology and Therapy**", "7", "2", "255", "264"
- 117) Buckanovich R.J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., **Katsaros D.**, O'Brien-Jenkins A., Gimotty P.A., Coukos G., "Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy", 2008, "**Nature Medicine**", "14", "1", "28", "36"
- 118) Zheng Y., **Katsaros D.**, Shan S.J.C., De La Longrais I.R., Porgiglia M., Scorilas A., Kim N.W., Wolfert R.L., Simon I., Li L., Feng Z., Diamandis E.P., "A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy", 2007, "**Clinical Cancer Research**", "13", "23", "6984", "6992"
- 119) Smith S., Su D., Rigault De La Longrais I.A., Schwartz P., Puopolo M., Rutherford T.J., Mor G., Yu H., **Katsaros D.**, "ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy", 2007, "**Journal of Clinical Oncology**", "25", "33", "5172", "5179"

- 120) Lu L., **Katsaros D.**, Rigault De La Longrais I.A., Sochirca O., Yu H., "Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis", 2007, "**Cancer Research**", "67", "21", "10117", "10122"
- 121) Brokaw J., **Katsaros D.**, Wiley A., Lu L., Su D., Sochirca O., de la Longrais I.A.R., Mayne S., Risch H., Yu H., "IGF-I in epithelial ovarian cancer and its role in disease progression", 2007, "**Growth Factors**", "25", "5", "346", "354"
- 122) Pignata S., Ferrandina G., Scarfone G., Scollo P., Odicino F., Selvaggi L., **Katsaros D.**, Frigerio L., Mereu L., Ghezzi F., Manzione L., Lauria R., Breda E., Marforio G., Ballardini M., Vernaglia Lombardi A., Sorio R., Tumolo S., Costa B., Magni G., Perrone F., Favalli G., "Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study", 2007, "**Oncology**", "71", "5-6", "320", "326"
- 123) Beeghly A.C., **Katsaros D.**, Wiley A.L., Rigault De La Longrais I.A., Prescott A.T., Chen H., Puopolo M., Rutherford T.J., Yu H., "IGF-II promoter methylation and ovarian cancer prognosis", 2007, "**Journal of Cancer Research and Clinical Oncology**", "133", "10", "713", "723"
- 124) Zhang L., Huang J., Yang N., Greshock J., Liang S., Hasegawa K., Giannakakis A., Poulos N., O'Brien-Jenkins A., **Katsaros D.**, Butzow R., Weber B.L., Coukos G., "Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer", 2007, "**Clinical Cancer Research**", "13", "18", "5314", "5321"
- 125) Simon I., **Katsaros D.**, Rigault de la Longrais I., Massobrio M., Scorilas A., Kim N.W., Sarno M.J., Wolfert R.L., Diamandis E.P., "B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression", 2007, "**Gynecologic Oncology**", "106", "2", "334", "341"
- 126) Buckanovich R.J., Sasaroli D., O'Brien-Jenkins A., Botbyl J., Hammond R., **Katsaros D.**, Sandaltzopoulos R., Liotta L.A., Gimotty P.A., Coukos G., "Tumor vascular proteins as biomarkers in ovarian cancer", 2007, "**Journal of Clinical Oncology**", "25", "7", "852", "861"
- 127) Shan S.J.C., Scorilas A., **Katsaros D.**, Diamandis E.P., "Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: Clinical and mechanistic aspects", 2007, "**British Journal of Cancer**", "96", "2", "362", "372"
- 128) Borgoño C.A., Michael I.P., Shaw J.L.V., Luo L.-Y., Ghosh M.C., Soosaipillai A., Grass L., **Katsaros D.**, Diamandis E.P., "Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14", 2007, "**Journal of Biological Chemistry**", "282", "4", "2405", "2422"
- 129) Coukos G., Alagkiozidis I., Kim S., Cadungog M., Adams S., Chu C., Conejo-Garcia J.R., Zou W., Curiel T., **Katsaros D.**, Zhang L., Gimotty P., "Immune biomarkers in ovarian cancer", 2007, "**Prognostic and Predictive Factors in Gynecologic Cancers**", "125", "140"
- 130) Gimotty P.A., Zhang L., Alagkiozidis I., Cadungog M., Adams S., Chu C., **Katsaros D.**, Coukos G., "Immune prognostic factors in ovarian cancer: Lessons from translational research", 2007, "**Disease Markers**", "23", "5-6", "445", "452"
- 131) Lu L., **Katsaros D.**, Wiley A., Rigault De La Longrais I.A., Puopolo M., Yu H., "Expression of MDR1 in epithelial ovarian cancer and its association with disease progression", 2007, "**Oncology Research**", "16", "8", "395", "403"
- 132) Lu L., **Katsaros D.**, Wiley A., Rigault de la Longrais I.A., Puopolo M., Schwartz P., Yu H., "Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer", 2006, "**Gynecologic Oncology**", "103", "3", "990", "995"

- 133) Shan S.J.C., Scorilas A., **Katsaros D.**, Rigault De La Longrais I., Massobrio M., Diamandis E.P., "Unfavorable prognostic value of human kallikrein 7 quantified by ELISA in ovarian cancer cytosols", 2006, "**Clinical Chemistry**", "52", "10", "1879", "1886"
- 134) Wiley A., **Katsaros D.**, Chen H., Rigault De La Longrais I.A., Beeghly A., Puopolo M., Singal R., Zhang Y., Amoako A., Zelterman D., Yu H., "Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential", 2006, "**Cancer**", "107", "2", "299", "308"
- 135) Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., Liang S., Naylor T.L., Barchetti A., Ward M.R., Yao G., Medina A., O'Brien-Jenkins A., **Katsaros D.**, Hatzigeorgiou A., Gimotty P.A., Weber B.L., Coukos G., "microRNAs exhibit high frequency genomic alterations in human cancer", 2006, "**Proceedings of the National Academy of Sciences of the United States of America**", "103", "24", "9136", "9141"
- 136) Santin A.D., Diamandis E.P., Bellone S., Marizzoni M., Bandiera E., Palmieri M., Papasakelariou C., **Katsaros D.**, Burnett A., Pecorelli S., "Overexpression of kallikrein 10 (hK10) in uterine serous papillary carcinomas", 2006, "**American Journal of Obstetrics and Gynecology**", "194", "5", "1296", "1302"
- 137) Zhang L., Huang J., Yang N., Liang S., Barchetti A., Giannakakis A., Cadungog M.G., O'Brien-Jenkins A., Massobrio M., Roby K.F., **Katsaros D.**, Gimotty P., Butzow R., Weber B.L., Coukos G., "Integrative genomic analysis of protein kinase C (PKC) family identifies PKC ϵ as a biomarker and potential oncogene in ovarian carcinoma", 2006, "**Cancer Research**", "66", "9", "4627", "4635"
- 138) Lu L., **Katsaros D.**, Wiley A., Rigault De La Longrais I.A., Risch H.A., Puopolo M., Yu H., "The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor- α expression to disease progression in epithelial ovarian cancer", 2006, "**Clinical Cancer Research**", "12", "4", "1208", "1214"
- 139) Fracchioli S., Puopolo M., Rigault De La Longrais I.A., Scozzafava M., Bogliatto F., Arisio R., Micheletti L., **Katsaros D.**, "Primary "breast-like" cancer of the vulva: A case report and critical review of the literature", 2006, "**International Journal of Gynecological Cancer**", "16", "SUPPL. 1", "423", "428"
- 140) Moll F., Millet C., Noël D., Orsetti B., Bardin A., **Katsaros D.**, Jorgensen C., Garcia M., Theillet C., Pujol P., François V., "Chordin is underexpressed in ovarian tumors and reduces tumor cell motility", 2006, "**FASEB Journal**", "20", "2", "240", "250"
- 141) Beeghly A., **Katsaros D.**, Chen H., Fracchioli S., Zhang Y., Massobrio M., Risch H., Jones B., Yu H., "Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival", 2006, "**Gynecologic Oncology**", "100", "2", "330", "337"
- 142) Wiley A., **Katsaros D.**, Fracchioli S., Yu H., "Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer", 2006, "**International Journal of Gynecological Cancer**", "16", "1", "210", "218"
- 143) Cattel L., Passera R., **Katsaros D.**, Medail M., Milla P., Ferrero A.M., "Pegylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: A pharmacokinetic study on alternate administration sequences", 2006, "**Anticancer Research**", "26", "1 B", "745", "750"
- 144) Yousef G.M., Obiezu C.V., Luo L., Magklara A., Borgoño C.A., Kishi T., Memari N., Michael I.P., Sidiropoulos M., Kurlender L., Economopolou K., Kapadia C., Komatsu N., Petraki C., Elliott M., Scorilas A., **Katsaros D.**, Levesque M.A., Diamandis E.P., "Human Tissue Kallikreins: From Gene Structure to Function and Clinical Applications", 2005, "**Advances in Clinical Chemistry**", "39", "11", "79"

- 145) Buda A., Fossati R., Colombo N., Fei F., Floriani I., Alletti D.G., **Katsaros D.**, Landoni F., Lissoni A., Malzoni C., Sartori E., Scollo P., Torri V., Zola P., Mangioni C., "Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: The SNAP01 (Studio neo-adiuvante portio) Italian collaborative study", 2005, "**Journal of Clinical Oncology**", "23", "18", "4137", "4145"
- 146) Berruti A., Bitossi R., Gorzegno G., Bottini A., Generali D., Milani M., **Katsaros D.**, Rigault De La Longrais I.A., Bellino R., Donadio M., Ardine M., Bertetto O., Danese S., Sarobba M.G., Farris A., Lorusso V., Dogliotti L., "Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines", 2005, "**British Journal of Cancer**", "92", "4", "634", "63"
- 147) **Katsaros D.**, Oletti M.V., Rigault de la Longrais I.A., Ferrero A., Celano A., Fracchioli S., Donadio M., Passera R., Cattel L., Bumma C., "Clinical and pharmacokinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent ovarian carcinoma", 2005, "**Annals of Oncology**", "16", "2", "300", "306"
- 148) Zhang L., Yang N., Huang J., Buckanovich R.J., Liang S., Barchetti A., Vezzani C., O'Brien-Jenkins A., Wang J., Ward M.R., Courreges M.C., Fracchioli S., Medina A., **Katsaros D.**, Weber B.L., Coukos G., "Transcriptional coactivator Drosophila Eyes Absent Homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth", 2005, "**Cancer Research**", "65", "3", "925", "932"
- 149) Sidiropoulos M., Pampalakis G., Sotiropoulou G., **Katsaros D.**, Diamandis E.P., "Downregulation of human kallikrein 10 (KLK10/NES1) by CpG island hypermethylation in breast, ovarian and prostate cancers", 2005, "**Tumor Biology**", "26", "6", "324", "336"
- 150) Berruti A., Bitossi R., Bottini A., Bonardi S., Donadio M., Nigro C., Bertetto O., Danese S., Bertone E., Sarobba M.G., Farris A., **Katsaros D.**, Castiglione F., Volpe T., Lattuada S., Mancarella S., Dogliotti L., "Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naïve metastatic breast cancer patients", 2005, "**European Journal of Cancer**", "41", "2", "249", "255"
- 151) Cunat S., Rabenoelina F., Daurès J.-P., **Katsaros D.**, Sasano H., Miller W.R., Maudelonde T., Pujol P., "Aromatase expression in ovarian epithelial cancers", 2005, "**Journal of Steroid Biochemistry and Molecular Biology**", "93", "1", "15", "24"
- 152) Conejo-Garcia J.R., Benencia F., Courreges M.-C., Kang E., Mohamed-Hadley A., Buckanovich R.J., Holtz D.O., Jenkins A., Na H., Zhang L., Wagner D.S., **Katsaros D.**, Carroll R., Coukos G., "Tumor-infiltrating dendritic cell precursors recruited by a β -defensin contribute to vasculogenesis under the influence of Vegf-A", 2004, "**Nature Medicine**", "10", "9", "950", "958"
- 153) **Katsaros D.**, Cho W., Singal R., Fracchioli S., Rigault De La Longrais I.A., Arisio R., Massobrio M., Smith M., Zheng W., Glass J., Yu H., "Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer", 2004, "**Gynecologic Oncology**", "94", "3", "685", "692"
- 154) Bardin A., Hoffmann P., Boule N., **Katsaros D.**, Vignon F., Pujol P., Lazennec G., "Involvement of estrogen receptor β in ovarian carcinogenesis", 2004, "**Cancer Research**", "64", "16", "5861", "5869"
- 155) Conejo-Garcia J.R., Benencia F., Courreges M.C., Gimoty P.A., Khang E., Buckanovich R.J., Frauwirth K.A., Zhang L., **Katsaros D.**, Thompson C.B., Levine B., Coukos G., "Ovarian Carcinoma Expresses the NKG2D Ligand Letal and Promotes the Survival and Expansion of CD28- Antitumor T Cells", 2004, "**Cancer Research**", "64", "6", "2175", "2182"
- 156) Porpiglia M., Vicelli R., Durando A., Fracchioli S., Puopolo M., **Katsaros D.**, Bellino R., Benedetto C., "Biologic therapy and epithelial ovarian cancer [La terapia biologica nel tumore epiteliale dell'ovaio]", 2004, "**Minerva Ginecologica**", "56", "1", "91", "104"

- 157) Kurlender L., Yousef G.M., Memari N., Robb J.-D., Michael I.P., Borgoño C., **Katsaros D.**, Stephan C., Jung K., Diamandis E.P., "Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer", 2004, "Tumor Biology", "25", "3", "149", "156"
- 158) Yousef G.M., White N.M.A., Kurlender L., Michael I., Memari N., Robb J.-D., **Katsaros D.**, Stephan C., Jung K., Diamandis E.P., "The kallikrein gene 5 splice variant 2 is a new biomarker for breast and ovarian cancer", 2004, "Tumor Biology", "25", "5-6", "221", "227"
- 159) Borgoño C.A., Grass L., Soosaipillai A., Yousef G.M., Petraki C.D., Howarth D.H.C., Fracchioli S., **Katsaros D.**, Diamandis E.P., "Human Kallikrein 14: A New Potential Biomarker for Ovarian and Breast Cancer", 2003, "Cancer Research", "63", "24", "9032", "9041"
- 160) Borgoño C.A., Fracchioli S., Yousef G.M., Rigault de la Longrais I.A., Luo L.-Y., Soosaipillai A., Puopolo M., Grass L., Scorilas A., Diamandis E.P., **Katsaros D.**, "Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma", 2003, "International Journal of Cancer", "106", "4", "605", "610"
- 161) Maggiora P., Lorenzato A., Fracchioli S., Costa B., Castagnaro M., Arisio R., **Katsaros D.**, Massobrio M., Comoglio P.M., Di Renzo M.F., "The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness", 2003, "Experimental Cell Research", "288", "2", "382", "389"
- 162) Yousef G.M., Scorilas A., **Katsaros D.**, Fracchioli S., Iskander L., Borgono C., Rigault de la Longrais I.A., Puopolo M., Massobrio M., Diamandis E.P., "Prognostic value of the human kallikrein gene 15 expression in ovarian cancer", 2003, "Journal of Clinical Oncology", "21", "16", "3119", "3126"
- 163) Zhang L., Yang N., **Katsaros D.**, Huang W., Park J.-W., Fracchioli S., Vezzani C., De la Longrais I.A.R., Yao W., Rubin S.C., Coukos G., "The oncogene phosphatidylinositol 3'-kinase catalytic subunit α promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma", 2003, "Cancer Research", "63", "14", "4225", "4231"
- 164) Zhang L., Yang N., Park J.-W., **Katsaros D.**, Fracchioli S., Cao G., O'Brien-Jenkins A., Randall T.C., Rubin S.C., Coukos G., "Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer", 2003, "Cancer Research", "63", "12", "3403", "3412"
- 165) Fracchioli S., Porpiglia M., Arisio R., Voglino G., **Katsaros D.**, "Oral squamous carcinoma in a patient with cervix cancer: Use of human papillomavirus analysis to differentiate synchronous versus metastatic tumor", 2003, "Gynecologic Oncology", "89", "3", "522", "525"
- 166) Scorilas A., Chiang P.M., **Katsaros D.**, Yousef G.M., Diamandis E.P., "Molecular characterization of a new gene, CEAL1, encoding for a carcinoembryonic antigen-like protein with a highly conserved domain of eukaryotic translation initiation factors", 2003, "Gene", "310", "1-2", "79", "89"
- 167) Yousef G.M., Polymeris M.-E., Yacoub G.M., Scorilas A., Soosaipillai A., Popalis C., Fracchioli S., **Katsaros D.**, Diamandis E.P., "Parallel overexpression of seven kallikrein genes in ovarian cancer", 2003, "Cancer Research", "63", "9", "2223", "2227"
- 168) Diamandis E.P., Scorilas A., Fracchioli S., Van Gramberen M., De Bruijn H., Henrik A., Soosaipillai A., Grass L., Yousef G.M., Stenman U.-H., Massobrio M., Van Der Zee A.G.J., Vergote I., **Katsaros D.**, "Human kallikrein 6 (hK6): A new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma", 2003, "Journal of Clinical Oncology", "21", "6", "1035", "1043"
- 169) Yousef G.M., Fracchioli S., Scorilas A., Borgoño C.A., Iskander L., Puopolo M., Massobrio M., Diamandis E.P., **Katsaros D.**, "Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer", 2003, "American Journal of Clinical Pathology", "119", "3", "346", "355"

- 170) Luo L.-Y., **Katsaros D.**, Scorilas A., Fracchioli S., Bellino R., Van Gramberen M., De Bruijn H., Henrik A., Stenman U.-H., Massobrio M., Van der Zee A.G.J., Vergote I., Diamandis E.P., "The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis", 2003, "**Cancer Research**", "63", "4", "807", "811"
- 171) Zhang L., Conejo-Garcia J.R., **Katsaros D.**, Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Lieberman M.N., Rubin S.C., Coukos G., "Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer", 2003, "**New England Journal of Medicine**", "348", "3", "203", "213"
- 172) Zhang L., Yang N., Conejo-Garcia J.-R., **Katsaros D.**, Mohamed-Hadley A., Fracchioli S., Schlienger K., Toll A., Levine B., Rubin S.C., Coukos G., "Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma", 2003, "**Clinical Cancer Research**", "9", "1", "264", "272"
- 173) Kyriakopoulou L.G., Yousef G.M., Scorilas A., **Katsaros D.**, Massobrio M., Fracchioli S., Diamandis E.P., "Prognostic value of quantitatively assessed KLK7 expression in ovarian cancer", 2003, "**Clinical Biochemistry**", "36", "2", "135", "143"
- 174) Piccinno R., Puopolo M., Rigault De La Longrais I.A., Fracchioli S., Massobrio M., **Katsaros D.**, "Growth factors in epithelial ovarian cancer [Fattori di crescita e carcinoma epiteliale ovarico]", 2002, "**Minerva Ginecologica**", "54", "1", "33", "52"
- 175) **Katsaros D.**, Yu H., Piccinno R., Puopolo M., Rigault De La Longrais I.A., Fracchioli S., Massobrio M., "IGFBP-3: Expression and prognostic significance in epithelial ovarian cancer [IGFBP-3: Espressione e significato prognostico nel carcinoma ovarico epiteliale]", 2002, "**Minerva Ginecologica**", "54", "1", "15", "24"
- 176) Moll F., **Katsaros D.**, Lazennec G., Hellio N., Roger P., Giacalone P.-L., Chalbos D., Maudelonde T., Rochefort H., Pujol P., "Estrogen induction and overexpression of fibulin-1C mRNA in ovarian cancer cells", 2002, "**Oncogene**", "21", "7", "1097", "1107"
- 177) Hoffman B.R., **Katsaros D.**, Scorilas A., Diamandis P., Fracchioli S., Rigault de la Longrais I.A., Colgan T., Puopolo M., Giardina G., Massobrio M., Diamandis E.P., "Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: A new independent unfavourable prognostic biomarker", 2002, "**British Journal of Cancer**", "87", "7", "763", "771"
- 178) Yousef G.M., Kyriakopoulou L.G., Scorilas A., Fracchioli S., Ghiringhello B., Zarghooni M., Chang A., Diamandis M., Giardina G., Hartwick W.J., Richiardi G., Massobrio M., Diamandis E.P., **Katsaros D.**, "Quantitative expression of the human kallikrein gene 9 (KLK9) in ovarian cancer: A new independent and favorable prognostic marker", 2001, "**Cancer Research**", "61", "21", "7811", "7818"
- 179) Scorilas A., Kyriakopoulou L., **Katsaros D.**, Diamandis E.P., "Cloning of a gene (SR-A1), encoding for a new member of the human Ser/Arg-rich family of pre-mRNA splicing factors: Overexpression in aggressive ovarian cancer", 2001, "**British Journal of Cancer**", "85", "2", "190", "198"
- 180) Yousef G.M., Magklara A., Chang A., Jung K., **Katsaros D.**, Diamandis E.P., "Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies", 2001, "**Cancer Research**", "61", "8", "3425", "3431"
- 181) **Katsaros D.**, Yu H., Levesque M.A., Danese S., Genta F., Richiardi G., Fracchioli S., Khosravi M.J., Diamandi A., Gordini G., Diamandis E.P., Massobrio M., "IGFBP-3 in epithelial ovarian carcinoma and its association with clinico-pathological features and patient survival", 2001, "**European Journal of Cancer**", "37", "4", "478", "485"

- 182) Kim H., Scorilas A., **Katsaros D.**, Yousef G.M., Massobrio M., Fracchioli S., Piccinno R., Gordini G., Diamandis E.P., "Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer", 2001, "**British Journal of Cancer**", "84", "5", "643", "650"
- 183) Magklara A., Scorilas A., **Katsaros D.**, Massobrio M., Yousef G.M., Fracchioli S., Danese S., Diamandis E.P., "The human KLK8 (neuropsin/ovasin) gene: Identification of two novel splice variants and its prognostic value in ovarian cancer", 2001, "**Clinical Cancer Research**", "7", "4", "806", "811"
- 184) Luo L.-Y., **Katsaros D.**, Scorilas A., Fracchioli S., Piccinno R., Rigault de la Longrais I.A., Howarth D.J.C., Diamandis E.P., "Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma", 2001, "**Clinical Cancer Research**", "7", "8", "2372", "2379"
- 185) Obiezu C.V., Scorilas A., Yousef G.M., Diamandis E.P., **Katsaros D.**, Massobrio M., Fracchioli S., Rigault de la Longrais I.A., Arisio R., "Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients", 2001, "**Clinical Cancer Research**", "7", "8", "2380", "2386"
- 186) Bellino R., Cortese P., Danese S., De Sanctis C., Durando A., Genta F., Grio R., Giardina G., **Katsaros D.**, Massobrio M., Richiardi G., Vicelli R., "Epidoxorubicin and paclitaxel as primary chemotherapy for T>3cm and T4 breast cancer patients", 2000, "**Anticancer Research**", "20", "6 C", "4825", "4828"
- 187) Levesque M.A., **Katsaros D.**, Massobrio M., Genta F., Yu H., Richiardi G., Fracchioli S., Durando A., Arisio R., Diamandis E.P., "Evidence for a dose-response effect between p53 (but not p21(WAF1/Cip1)) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy", 2000, "**Clinical Cancer Research**", "6", "8", "3260", "3270"
- 188) **Katsaros D.**, Fracchioli S., Arese P., Enria R., Cassinelli P., Mingrone K., Piccinno R., De la Longrais L.A.R., Massobrio M., "Chemoresistance in ovarian cancer. State of art and perspectives [La chemioresistenza nel carcinoma dell'ovaio]", 1999, "**Minerva Ginecologica**", "51", "12", "483", "499"
- 189) **Katsaros D.**, Fracchioli S., Arts H.J.G., De Vries E.G.E., Danese S., Richiardi G., Arisio R., Gordini G., Van der Zee A.G.J., Suurmeijer A.J.H., Massobrio M., "Expression and prognostic value of drug resistance-associated markers P-gp, Mrp1, Mrp2 and Lrp in ovarian cancer [Espressione e significato prognostico dei markers di chemioresistenza P-gp, Mrp1, Mrp2 e Lrp nei carcinomi ovarici]", 1999, "**Minerva Ginecologica**", "51", "12", "463", "470"
- 190) Fracchioli S., **Katsaros D.**, Maggiora P., Di Renzo M.F., Massobrio M., "Expression of Ron and Met proto-oncogenes in epithelial ovarian cancer: Clinical implications [Valutazione dell'espressione dei proto-oncogeni Ron e Met nei tumori epiteliali ovarici]", 1999, "**Minerva Ginecologica**", "51", "10", "359", "364"
- 191) Arts H.J.G., **Katsaros D.**, De Vries E.G.E., Massobrio M., Genta F., Danese S., Arisio R., Scheper R.J., Kool M., Scheffer G.L., Willemse P.H.B., Van Der Zee A.G.J., Suurmeijer A.J.H., "Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma", 1999, "**Clinical Cancer Research**", "5", "10", "2798", "2805"
- 192) Lianidou E.S., Levesque M.A., **Katsaros D.**, Angelopoulou K., Yu H., Genta F., Arisio R., Massobrio M., Bharaj B., Diamandis E.P., "Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma", 1999, "**Anticancer Research**", "19", "1 B", "749", "756"

- 193) Lianidous E.S., Angelopoulou K., **Katsaros D.**, Durando A., Massdario M., Diamandis E.P., "Erratum: Fragment analysis of the p53 gene in ovarian tumors (Clinical Biochemistry (1998) 31:7 (551-553))", 1999, "**Clinical Biochemistry**", "32", "2", "155"
- 194) Lianidou E.S., Angelopoulou K., **Katsaros D.**, Durando A., Massdario M., Diamandis E.P., "Fragment analysis of the p53 gene in ovarian tumors", 1998, "**Clinical Biochemistry**", "31", "7", "551", "553"
- 195) **Katsaros D.**, Melegos D.N., Diamandis E.P., "Prostate specific antigen production by breast tumors after induction with oral contraceptives", 1998, "**Clinical Biochemistry**", "31", "4", "285", "288"
- 196) Levesque M.A., **Katsaros D.**, Yu H., Gai M., Genta F., Roagna R., Ponzzone R., Massobrio M., Sismondi P., Diamandis E.P., "Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients", 1998, "**International Journal of Cancer**", "79", "2", "147", "152"
- 197) Angelopoulou K., Levesque M.A., **Katsaros D.**, Shipman R., Diamandis E.P., "Exon 5 of the p53 gene is a target for deletions in ovarian cancer", 1998, "**Clinical Chemistry**", "44", "1", "72", "77"
- 198) Bartlett J.M., Langdon S.P., Scott W.N., Love S.B., Miller E.P., **Katsaros D.**, Smyth J.F., Miller W.R., "Transforming growth factor- β isoform expression in human ovarian tumours", 1997, "**European Journal of Cancer**", "33", "14", "2397", "2403"
- 199) Courjal F., Louason G., Speiser P., **Katsaros D.**, Zeillinger R., Theillet C., "Cyclin gene amplification and overexpression in breast and ovarian cancers: Evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors", 1996, "**International Journal of Cancer**", "69", "4", "247", "253"
- 200) Bartlett J.M.S., Langdon S.P., Simpson B.J.B., Stewart M., **Katsaros D.**, Sismondi P., Love S., Scott W.N., Williams A.R.W., Lessells A.M., Macleod K.G., Smyth J.F., Miller W.R., "The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer", 1996, "**British Journal of Cancer**", "73", "3", "301", "306"
- 201) Courjal F., Cuny M., Rodriguez C., Louason G., Speiser P., **Katsaros D.**, Tanner M.M., Zeillinger R., Theillet C., "DNA amplifications at 20q 13 and MDM2 define distinct subsets of evolved breast and ovarian tumours", 1996, "**British Journal of Cancer**", "74", "12", "1984", "1989"
- 202) Simpson B.J.B., Ramage A.D., Hulme M.J., Burns D.J., **Katsaros D.**, Langdon S.P., Miller W.R., "Cyclic adenosine 3',5'-monophosphate-binding proteins in human ovarian cancer: Correlations with clinicopathological features", 1996, "**Clinical Cancer Research**", "2", "1", "201", "206"
- 203) Zarghami N., Gai M., Yu H., Roagna R., Ponzzone R., **Katsaros D.**, Sismondi P., Diamandis E.P., "Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients", 1996, "**British Journal of Cancer**", "73", "3", "386", "390"
- 204) Yu H., Diamandis E.P., Levesque M.A., Gai M., **Katsaros D.**, Roagna R., Ponzzone R., Sismondi P., Sutherland D.J.A., "Prostate-specific Antigen Is a New Favorable Prognostic Indicator for Women with Breast Cancer", 1995, "**Cancer Research**", "55", "10", "2104", "2110"
- 205) Zarghami N., **Katsaros D.**, Yu H., Diamandis E.P., "Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma.", 1995, "**The Canadian journal of oncology**", "5", "3", "401", "407"
- 206) Gai M., Yu H., Roagna R., Ponzzone R., **Katsaros D.**, Levesque M.A., Diamandis E.P., "Prostate-specific antigen in serum of women with breast cancer", 1995, "**British Journal of Cancer**", "72", "3", "728", "731"

- 207) **Katsaros D.**, Theillet C., Zola P., Louason G., Sanfilippo B., Isaia E., Arisio R., Giardina G., Sismondi P., "Concurrent abnormal expression of erbB-2, myc and ras genes is associated with poor outcome of ovarian cancer patients", 1995, "**Anticancer Research**", "15", "4", "1501", "1510"
- 208) **Katsaros D.**, Zola P., Sinistrero G., Bergamino T., Rumore A., Ferrero A., Bau M.-G., Sismondi P., "Weekly cisplatin induction chemotherapy in high-risk cervical cancer patients with bulky tumor: A phase II study", 1995, "**International Journal of Oncology**", "6", "5", "1033", "1038"
- 209) Levesque M.A., **Katsaros D.**, Yu H., Zola P., Sismondi P., Giardina G., Diamandis E.P., "Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma", 1995, "**Cancer**", "75", "6", "1327", "1338"
- 210) Yu H., Diamandis E.P., Levesque M., Sismondi P., Zola P., **Katsaros D.**, "Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary", 1994, "**Journal of Clinical Laboratory Analysis**", "8", "4", "251", "253"
- 211) Di Renzo M.F., Olivero M., **Katsaros D.**, Crepaldi T., Gaglia P., Zola P., Sismondi P., Comoglio P.M., "Overexpression of the MET/HGF receptor in ovarian cancer", 1994, "**International Journal of Cancer**", "58", "5", "658", "662"
- 212) Genta F., Ghiringhello B., Botta G., De Sanctis C., **Katsaros D.**, Mano M.P., Sismondi P., "Tissue CEA and TPA expression in stage I breast cancer", 1994, "**International Journal of Oncology**", "4", "2", "449", "452"
- 213) Zola P., Schnapper G., **Katsaros D.**, Genta F., Bau M.G., Ferrero A.M., Galletto L., Sismondi P., "AVM (Adriamycin, Vinblastine, Methotrexate) neoadjuvant chemotherapy in advanced or inflammatory carcinoma of the breast", 1993, "**International Journal of Oncology**", "3", "5", "869", "872"
- 214) Theillet C., Adelaide J., Louason G., Bonnet-Dorion F., Jacquemier J., Adnane J., Longy M., **Katsaros D.**, Sismondi P., Gaudray P., Birnbaum D., "FGFRI and PLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers", 1993, "**Genes, Chromosomes and Cancer**", "7", "4", "219", "226"
- 215) Zola P., Bergamino T., **Katsaros D.**, Ferrero A., Ciancio A., Bellora G., Sismondi P., "Phase II trial with 5-fluorouracil and high-dose folinic acid, using new sequential dosing schedule, in pretreated advanced breast cancer patients", 1992, "**European Journal of Gynaecological Oncology**", "13", "6", "527", "532"
- 216) Zola P., Volpe T., Luparia E., Rumore A., **Katsaros D.**, Sismondi P., "Localization and management of occult breast lesions", 1991, "**European Journal of Gynaecological Oncology**", "12", "1", "63", "68"
- 217) Volpe T., **Katsaros D.**, Bergamino T., Rumore A., Zola P., Sismondi P., "Occult mammary lesions: preoperative localization. Review of the literature [Lesioni mammarie occulte: localizzazione preoperatoria. Analisi della letteratura.]", 1990, "**Minerva ginecologica**", "42", "10", "393", "397"
- 218) Ally S., Clair T., **Katsaros D.**, Tortora G., Yokozaki H., Cho-Chung Y.S., Finch R.A., Avery T.L., "Inhibition of Growth and Modulation of Gene Expression in Human Lung Carcinoma in Athymic Mice by Site-selective 8-Cl-Cyclic Adenosine Monophosphate", 1989, "**Cancer Research**", "49", "20", "5650", "5655"
- 219) Tortora G., Clair T., **Katsaros D.**, Ally S., Colamonici O., Neckers L.M., Tagliaferri P., Jahnsen T., Robins R.K., Cho-Chung Y.S., "Induction of megakaryocytic differentiation and modulation of protein kinase gene expression by site-selective cAMP analogs in K-562 human leukemic cells", 1989, "**Proceedings of the National Academy of Sciences of the United States of America**", "86", "8", "2849", "2852"

- 220) Cho-Chung Y.S., Clair T., Tagliaferri P., Ally S., **Katsaros D.**, Tortora G., Neckers L., Avery T.L., Crabtree G.W., Robins R.K., "Site-selective cyclic AMP analogs as new biological tools in growth control, differentiation, and proto-oncogene regulation", 1989, "**Cancer Investigation**", "7", "2", "161", "177"
- 221) Tagliaferri P., **Katsaros D.**, Clair T., Ally S., Tortora G., Neckers L., Rubalcava B., Parandoosh Z., Chang Y.-A., Revankar G.R., Crabtree G.W., Robins R.K., Cho-Chung Y.S., "Synergistic Inhibition of Growth of Breast and Colon Human Cancer Cell Lines by Site-selective Cyclic AMP Analogues", 1988, "**Cancer Research**", "48", "6", "1642", "1650"
- 222) **Katsaros D.**, Ally S., Cho-Chung Y.S., "Site selective cyclic amp analogues are antagonistic to estrogen stimulation of growth and proto-oncogene expression in human breast-cancer cells", 1988, "**International Journal of Cancer**", "41", "6", "863", "867"
- 223) Tagliaferri P., **Katsaros D.**, Clair T., Neckers L., Robins R.K., Yoon Sang Cho-Chung, "Reverse transformation of Harvey murine sarcoma virus transformed NIH/3T3 cells by site-selective cyclic AMP analogs", 1988, "**Journal of Biological Chemistry**", "263", "1", "409", "416"
- 224) Ally S., Tortora G., Clair T., Grieco D., Merlo G., **Katsaros D.**, OGREID D., Doskeland S.O., Jahnsen T., Cho-Chung Y.S., "Selective modulation of protein kinase isozymes by the site-selective analog 8-chloroadenosine 3',5'-cyclic monophosphate provides a biological means for control of human colon cancer cell growth", 1988, "**Proceedings of the National Academy of Sciences of the United States of America**", "85", "17", "6319", "6322"
- 225) **Katsaros D.**, Tortora G., Tagliaferri P., Clair T., Ally S., Neckers L., Robins R.K., Cho-Chung Y.S., "Site-selective cyclic AMP analogs provide a new approach in the control of cancer cell growth", 1987, "**FEBS Letters**", "223", "1", "97", "103"

August 29, 2023, Turin, ITALY